Bausch Health's Securities Litigation Casts Shadow Over B+L's Future As Independent Firm

For all B+L has going for it, including consumer health eye health and vision care products as its sales driver, it could be stymied by investors alleging Bausch Health conducted fraudulent conveyance by spinning out B+L through an IPO in 2022.

• Source: Shutterstock

Bausch + Lomb Corp.’s latest results coming on 3 May will mark the start of its second year operating independently of former parent firm and still majority owner Bausch Health Companies Inc. But the Canadian firm’s independence is under challenge.

JP Morgan analysts in a 16 April research report noted that for all that B+L has going for it, including...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Legal

More from Policy & Regulation